Aperio Group LLC Acquires New Position in AxoGen, Inc. (AXGN)
Aperio Group LLC acquired a new stake in shares of AxoGen, Inc. (NASDAQ:AXGN) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 14,575 shares of the medical equipment provider’s stock, valued at approximately $412,000.
Several other large investors also recently added to or reduced their stakes in the company. Wells Fargo & Company MN raised its holdings in shares of AxoGen by 17.2% during the second quarter. Wells Fargo & Company MN now owns 46,745 shares of the medical equipment provider’s stock valued at $783,000 after acquiring an additional 6,848 shares in the last quarter. Alliancebernstein L.P. bought a new position in shares of AxoGen during the second quarter valued at approximately $317,000. Ameriprise Financial Inc. bought a new position in shares of AxoGen during the second quarter valued at approximately $1,412,000. Nationwide Fund Advisors raised its holdings in shares of AxoGen by 5.5% during the second quarter. Nationwide Fund Advisors now owns 14,874 shares of the medical equipment provider’s stock valued at $249,000 after acquiring an additional 774 shares in the last quarter. Finally, New York State Common Retirement Fund raised its holdings in shares of AxoGen by 26.6% during the second quarter. New York State Common Retirement Fund now owns 31,400 shares of the medical equipment provider’s stock valued at $526,000 after acquiring an additional 6,599 shares in the last quarter. 69.57% of the stock is owned by hedge funds and other institutional investors.
AxoGen, Inc. (NASDAQ AXGN) opened at $32.95 on Monday. The company has a debt-to-equity ratio of 1.93, a quick ratio of 2.95 and a current ratio of 3.55. The company has a market capitalization of $1,140.00, a P/E ratio of -106.29 and a beta of 0.58. AxoGen, Inc. has a twelve month low of $9.55 and a twelve month high of $35.40.
A number of brokerages recently commented on AXGN. Lake Street Capital set a $38.00 target price on AxoGen and gave the company a “buy” rating in a report on Friday. Cantor Fitzgerald set a $37.00 target price on AxoGen and gave the company a “buy” rating in a report on Monday, January 8th. JMP Securities upped their target price on AxoGen from $27.00 to $34.00 and gave the company a “market outperform” rating in a report on Thursday. BidaskClub upgraded AxoGen from a “buy” rating to a “strong-buy” rating in a report on Friday, February 23rd. Finally, William Blair began coverage on AxoGen in a report on Monday, February 5th. They set an “outperform” rating for the company. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. AxoGen presently has a consensus rating of “Buy” and a consensus target price of $31.71.
In other AxoGen news, Director Jamie Mark Grooms sold 21,290 shares of the stock in a transaction on Wednesday, December 6th. The stock was sold at an average price of $26.22, for a total value of $558,223.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last quarter, insiders sold 313,397 shares of company stock valued at $8,386,910. 9.33% of the stock is owned by corporate insiders.
ILLEGAL ACTIVITY WARNING: This piece was posted by Watch List News and is owned by of Watch List News. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be read at https://www.watchlistnews.com/aperio-group-llc-acquires-new-position-in-axogen-inc-axgn/1908390.html.
AxoGen, Inc provides surgical solutions for peripheral nerve injuries. The companys surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
Want to see what other hedge funds are holding AXGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AxoGen, Inc. (NASDAQ:AXGN).
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.